Sign In
Buy GMED
$77.95
-0.300 (-0.383%)
At Close: Jun 03, 2026
Globus Medical: Q4 Revenue Tops Forecast
06:52pm, Thursday, 20'th Feb 2025
Medical technologies specialist Globus Medical (GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) o
Globus Medical Reports Fourth Quarter and Full Year 2024 Results
04:15pm, Thursday, 20'th Feb 2025
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year e
Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:20am, Monday, 17'th Feb 2025
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimate
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Thursday, 13'th Feb 2025
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
09:15am, Tuesday, 11'th Feb 2025
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp.
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
09:30am, Thursday, 06'th Feb 2025
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
10:45am, Wednesday, 05'th Feb 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
04:35pm, Thursday, 30'th Jan 2025
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 23'rd Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
09:01am, Tuesday, 21'st Jan 2025
GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
01:16pm, Monday, 20'th Jan 2025
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Globus Medical (GMED) is a Strong Growth Stock
10:51am, Monday, 20'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
11:26am, Friday, 10'th Jan 2025
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
04:30pm, Wednesday, 08'th Jan 2025
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quart
